
- /
- Supported exchanges
- / F
- / 3G0.F
Altimmune Inc (3G0 F) stock market data APIs
Altimmune Inc Financial Data Overview
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Altimmune Inc data using free add-ons & libraries
Get Altimmune Inc Fundamental Data
Altimmune Inc Fundamental data includes:
- Net Revenue: 52 000
- EBITDA: -99 191 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-10
- EPS/Forecast: -0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Altimmune Inc News

Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
Altimmune, Inc GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects w...


Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Altimmune, Inc Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatment Over 30% of subjects achieved 20% or more weight loss o...

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
Altimmune, Inc Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) ...

Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
Altimmune, Inc GAITHERSBURG, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 20...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.